Format

Send to

Choose Destination
Trends Genet. 2018 Feb;34(2):101-110. doi: 10.1016/j.tig.2017.11.001. Epub 2017 Nov 24.

Mitochondrial Genome Engineering: The Revolution May Not Be CRISPR-Ized.

Author information

1
Medical Research Council (MRC) Mitochondrial Biology Unit, University of Cambridge, Cambridge, UK. Electronic address: payam.gammage@mrc-mbu.cam.ac.uk.
2
Miller School of Medicine, University of Miami, Miami, FL, USA. Electronic address: cmoraes@med.miami.edu.
3
Medical Research Council (MRC) Mitochondrial Biology Unit, University of Cambridge, Cambridge, UK. Electronic address: michal.minczuk@mrc-mbu.cam.ac.uk.

Abstract

In recent years mitochondrial DNA (mtDNA) has transitioned to greater prominence across diverse areas of biology and medicine. The recognition of mitochondria as a major biochemical hub, contributions of mitochondrial dysfunction to various diseases, and several high-profile attempts to prevent hereditary mtDNA disease through mitochondrial replacement therapy have roused interest in the organellar genome. Subsequently, attempts to manipulate mtDNA have been galvanized, although with few robust advances and much controversy. Re-engineered protein-only nucleases such as mtZFN and mitoTALEN function effectively in mammalian mitochondria, although efficient delivery of nucleic acids into the organelle remains elusive. Such an achievement, in concert with a mitochondria-adapted CRISPR/Cas9 platform, could prompt a revolution in mitochondrial genome engineering and biological understanding. However, the existence of an endogenous mechanism for nucleic acid import into mammalian mitochondria, a prerequisite for mitochondrial CRISPR/Cas9 gene editing, remains controversial.

KEYWORDS:

CRISPR/Cas9; RNA import; mitoTALEN; mitochondria; mtDNA; mtZFN

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center